VivoSeq
Other

Torticollis

10

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

Torticollis is an early-stage landscape with 10 programs across 9 companies. The most active players are AbbVie, Eisai, Vitae Pharmaceuticals Inc., an Allergan affiliate. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3M

Merz Pharmaceuticals GmbH

1 program

Phase 3R

Revance Therapeutics, Inc.

1 program

Phase 3UCB logo

UCB

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Withdrawn1 · 25%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis
Completed·Eisai logoEisai·Phase 2·NCT00165776·133 enrolled
Ultrasound Guided Intermediate Cervical Plexus Block for Congenital Muscular Torticollis
Completed·—·Phase 4·NCT02651311·32 enrolled
Comparative Trial of Botox in the Management of Children With Congenital Muscular Torticollis
Withdrawn·UUniversity of British Columbia·Phase 1·NCT00175604
The Effects of Weight Shift Training on the Symmetry of Upper Extremity Weight Bearing in the Prone Position in Infants With Congenital Muscular Torticollis
Not yet recruiting·SSahmyook University·Preclinical·NCT07663721·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)